Improving safety of new diabetes medications for patients with diabetes and kidney disease
Official title: Optimizing the Safety of the Newer Diabetes Medications in Patients with Diabetes and Kidney Disease
Funded at Brigham and Women's Hospital · NIH-11077255 · Data updated 2026-11-12
This study is looking at how safe newer diabetes medications are for people who have both diabetes and kidney disease, especially older adults, so that doctors can confidently prescribe them to more patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 19, 2024 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $691,774 |
| NIH project number | 5R01DK135706-02 |
| Project ID | NIH-11077255 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with diabetes who also have kidney disease, particularly those who are older and may be taking multiple medications.
✕Less likely to help
Patients without diabetes or kidney disease, or those who are not on any medications, may not benefit from this research.
What this research studies
This research investigates the safety of newer diabetes medications, specifically sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA), in patients who have both diabetes and kidney disease. The study aims to address the lack of safety data for these medications in real-world settings, particularly among older patients with multiple health issues. By utilizing large national healthcare databases, the research will analyze the effects of these medications on a diverse group of patients, focusing on minimizing adverse events and drug interactions. The goal is to create a framework that ensures these medications can be safely prescribed to a broader range of patients with kidney disease.
Why it matters
Potential benefit: If successful, this research could lead to safer prescribing practices for diabetes medications in patients with kidney disease, ultimately improving their health outcomes.
How similar studies have gone: Previous research has shown promising results in the safety and efficacy of similar diabetes medications, but this study aims to fill critical gaps in safety data for high-risk populations.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Paik, Julie — Brigham and Women's Hospital
- Study coordinator: Paik, Julie
Related research
Other NIH-funded projects on the same topics.
-
Multi-omics study of diabetes, kidney disease, and environment in diverse adults
Researchers are building a diverse group of adults to learn how environment and biology together affect diabetes and kidney disease, with hopes to improve care for people like them.
-
PFAS exposure and kidney disease risk in teens with type 2 diabetes
Aging and kidney health study in youths with type 2 diabetes to see how a common chemical (PFAS) affects kidney risk and how to prevent or treat it.
-
New kidney biomarkers to catch type 1 diabetes kidney disease early
This study looks for tiny clues in urine and blood that predict kidney trouble early in people with type 1 diabetes.
-
Unrecognized Primary Aldosteronism and Kidney Disease in Diabetes
A study at Brigham and Women’s Hospital will explore whether unrecognized primary aldosteronism contributes to kidney disease and heart risk in people with diabetes.
-
Rapid, multi-drug initiation for people with CKD and type 2 diabetes
A small study will try starting several key diabetes and kidney medicines at the same time in adults with CKD and type 2 diabetes to see if this fast plan is safe and helpful.
-
Role of a suPAR fragment in diabetes and kidney disease
A medical research project is testing whether a specific protein fragment in the blood harms both the pancreas and kidneys, which could lead to future therapies for adults with diabetes and kidney disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.